Regeneron Pharmaceuticals Inc (REGN)vsWest Pharmaceutical Services Inc (WST)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+0.97%
HEALTHCARE · Cap: $78.41B
WST
West Pharmaceutical Services Inc
$247.02
+0.71%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 367% more annual revenue ($14.34B vs $3.07B). REGN leads profitability with a 31.4% profit margin vs 16.1%. REGN appears more attractively valued with a PEG of 1.56. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$247.02
$178.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
REGN profiles as a value stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.18 — expect wider price swings.
WST is growing revenue faster at 7.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 55/100), backed by strong 31.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?